Evaluation of Floxuridine Oligonucleotide Conjugates Carrying Potential Enhancers of Cellular Uptake.

Apoptosis / drug effects Cell Proliferation / drug effects Cytotoxins / chemistry Floxuridine / chemistry HeLa Cells Hep G2 Cells Humans Oligonucleotides / chemistry
5-fluoro-2′-deoxyuridine GalNAc cancer treatment cholesterol conjugation delivery enhancers folic acid palmitic acid

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
26 May 2021
Historique:
received: 31 03 2021
revised: 21 05 2021
accepted: 25 05 2021
entrez: 2 6 2021
pubmed: 3 6 2021
medline: 22 6 2021
Statut: epublish

Résumé

Conjugation of small molecules such as lipids or receptor ligands to anti-cancer drugs has been used to improve their pharmacological properties. In this work, we studied the biological effects of several small-molecule enhancers into a short oligonucleotide made of five floxuridine units. Specifically, we studied adding cholesterol, palmitic acid, polyethyleneglycol (PEG 1000), folic acid and triantennary

Identifiants

DOI: 10.3390/ijms22115678 PMID: 34073599 PMC: PMC8199350
pubmed: 34073599
pii: ijms22115678
doi: 10.3390/ijms22115678
pmc: PMC8199350
pii:
doi:

Substances chimiques

Cytotoxins 0
Oligonucleotides 0
Floxuridine 039LU44I5M

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Spanish Ministerio de Ciencia e Innovación
ID : CTQ2017-84415-R
Organisme : Generalitat de Catalunya
ID : 2017SGR114
Organisme : CIBER-BBN
ID : CB06/01/0019
Organisme : Spanish Ministerio de Ciencia e innovación
ID : PRE2018-084056

Références

Nucleic Acids Res. 1994 Nov 11;22(22):4810-7
pubmed: 7984434
Nucleic Acids Res. 2009 Mar;37(4):e28
pubmed: 19158188
J Am Chem Soc. 2010 Mar 31;132(12):4259-65
pubmed: 20218672
Artif Cells Nanomed Biotechnol. 2017 May;45(3):568-573
pubmed: 27027552
Bioorg Med Chem. 2017 Jan 1;25(1):175-186
pubmed: 27810441
Int J Pharm. 2014 Nov 20;475(1-2):597-604
pubmed: 25219859
Eur J Med Chem. 2016 Jun 10;115:41-52
pubmed: 26994842
Angew Chem Int Ed Engl. 2018 Jul 16;57(29):8994-8997
pubmed: 29923269
Nucleic Acids Res. 2019 Jul 9;47(12):6045-6058
pubmed: 31076766
Mol Ther. 2020 Aug 5;28(8):1759-1771
pubmed: 32592692
Mol Ther Nucleic Acids. 2017 Mar 17;6:116-132
pubmed: 28325278
Expert Opin Drug Deliv. 2018 Jun;15(6):629-640
pubmed: 29727206
Nucleic Acid Ther. 2019 Oct;29(5):245-255
pubmed: 31158063
Nucleic Acid Ther. 2018 Jun;28(3):109-118
pubmed: 29792572
Invest New Drugs. 2000 Nov;18(4):299-313
pubmed: 11081567
Exp Hematol. 2013 Feb;41(2):180-188.e4
pubmed: 23085462
Pharm Res. 2003 Sep;20(9):1381-8
pubmed: 14567631
Mol Cancer Ther. 2009 May;8(5):1015-25
pubmed: 19383854
Bioorg Med Chem Lett. 2018 Aug 15;28(15):2652-2654
pubmed: 30042045
J Am Chem Soc. 2013 Feb 27;135(8):2907-10
pubmed: 23379791
Nucleic Acids Res. 2020 May 7;48(8):4382-4395
pubmed: 32182359
Mol Pharm. 2011 Dec 5;8(6):2193-203
pubmed: 21985606
Cancer Res. 2003 Dec 15;63(24):8791-812
pubmed: 14695196
Bioorg Med Chem Lett. 2012 Jul 15;22(14):4497-501
pubmed: 22738636
J Pharmacol Exp Ther. 2006 May;317(2):797-805
pubmed: 16452392
Drug Discov Today. 2005 Nov 1;10(21):1451-8
pubmed: 16243265
Bioconjug Chem. 2021 Feb 17;32(2):350-366
pubmed: 33543930
Future Oncol. 2016 Sep;12(17):2009-20
pubmed: 27279153
J Immunol. 2019 Jan 1;202(1):11-19
pubmed: 30587569
Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):7859-63
pubmed: 8058724
Curr Opin Biomed Eng. 2020 Mar;13:76-83
pubmed: 32642625
Cancer Drug Resist. 2019;2:994-1001
pubmed: 31930190
Br J Cancer. 2010 Jul 27;103(3):340-6
pubmed: 20606684
Nat Rev Cancer. 2003 May;3(5):330-8
pubmed: 12724731
Nat Biotechnol. 2007 Oct;25(10):1149-57
pubmed: 17873866
Nucleic Acids Res. 2019 Jul 9;47(12):6029-6044
pubmed: 31127296
EMBO Mol Med. 2018 Oct;10(10):
pubmed: 30190334
Mol Cancer Ther. 2005 Apr;4(4):659-67
pubmed: 15827340
Bioconjug Chem. 2019 Feb 20;30(2):366-383
pubmed: 30608140
Nanoscale. 2018 Apr 19;10(15):7238-7249
pubmed: 29632908
Signal Transduct Target Ther. 2020 Jun 19;5(1):101
pubmed: 32561705
Ann Oncol. 2011 Dec;22(12):2604-2609
pubmed: 21415237
J Drug Deliv. 2012;2012:103973
pubmed: 22645686
PLoS One. 2014 Nov 04;9(11):e110813
pubmed: 25369131
J Clin Epidemiol. 2014 Aug;67(8):850-7
pubmed: 24831050
Nano Res. 2018 Oct;11(10):5519-5534
pubmed: 30740197

Auteurs

Anna Aviñó (A)

Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Jordi Girona 18-26, E-08034 Barcelona, Spain.
Networking Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Jordi Girona 18-26, E-08034 Barcelona, Spain.

Anna Clua (A)

Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Jordi Girona 18-26, E-08034 Barcelona, Spain.
Networking Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Jordi Girona 18-26, E-08034 Barcelona, Spain.
ORCID: 0000-0002-8971-9841

Maria José Bleda (MJ)

Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Jordi Girona 18-26, E-08034 Barcelona, Spain.
ORCID: 0000-0002-1173-1840

Ramon Eritja (R)

Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Jordi Girona 18-26, E-08034 Barcelona, Spain.
Networking Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Jordi Girona 18-26, E-08034 Barcelona, Spain.
ORCID: 0000-0001-5383-9334

Carme Fàbrega (C)

Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Jordi Girona 18-26, E-08034 Barcelona, Spain.
Networking Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Jordi Girona 18-26, E-08034 Barcelona, Spain.
ORCID: 0000-0003-3816-7634

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › Evaluation of Floxuridine Oligonucleotide...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › Evaluation of Floxuridine Oligonucleotide...
questionsmedicales.fr › Actions chimiques et utilisations › Actions toxiques › Noxas › Cytotoxines › Evaluation of Floxuridine Oligonucleotide...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Nucléosides pyrimidiques › Désoxyuridine › Floxuridine › Evaluation of Floxuridine Oligonucleotide...
questionsmedicales.fr › Cellules › Cellules épithéliales › Cellules HeLa › Evaluation of Floxuridine Oligonucleotide...
questionsmedicales.fr › Cellules › Cellules épithéliales › Hépatocytes › Cellules HepG2 › Evaluation of Floxuridine Oligonucleotide...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Evaluation of Floxuridine Oligonucleotide...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléotides › Polynucléotides › Oligonucléotides › Evaluation of Floxuridine Oligonucleotide...